Sionna Therapeutics said it started a Phase 2a proof-of-concept trial evaluating the results of SION-719, a nucleotide binding domain (NBD1) stabilizer, when added to Trikafta, which is the current ...

Tuesday’s trading session is showcasing significant movements across various market cap categories, with mega-cap stocks like United Tech (RTX) and large-cap stocks such as General Motors (GM) ...

Ex-Citadel, Millennium, Tower Research Guys Join Young Crypto Hedge Fund Manager (eFinancialCareers) George Weiss, Former ...

This article summarizes the most notable insider buys and sells from Monday, October 20, 2025, for US stocks.

SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc ...

SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 ...

Michael Cloonan, directeur, président et directeur général de Sionna Therapeutics , a vendu 25 200 actions de la société les ...

Michael Cloonan, Président et PDG de Sionna Therapeutics, Inc. (NASDAQ:SION), a vendu un total de 25.200 actions ordinaires les 15 et 16 octobre 2025. Les ventes ont été exécutées à des prix allant de ...

Fintel reports that on October 17, 2025, Freedom Capital Markets initiated coverage of Sionna Therapeutics (NasdaqGM:SION) with a Buy recommendation. Analyst Price Forecast Suggests 18.46% Upside As ...

Freedom Capital initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $38 price target Completed Phase 1 studies have shown clean ...

Detailed price information for Sionna Therapeutics Inc (SION-Q) from The Globe and Mail including charting and trades.

Suite à ces transactions, Atlas Venture Fund XI, L.P. détient indirectement 2.619.185 actions de Sionna Therapeutics, tandis qu’Atlas Venture Opportunity Fund II, L.P. détient indirectement 751.664 ...